Cargando…

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections

BACKGROUND: Teicoplanin is a glycopeptide antibiotic that has been used to treat serious, invasive infections caused by Gram-positive bacteria. The area under the drug concentration–time curve (AUC)/minimum inhibitory concentration (MIC) was identified as a pharmacokinetic–pharmacodynamic (PK–PD) pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Kazuaki, Watanabe, Erika, Kanazawa, Naoko, Fukamizu, Tomohide, Shigemi, Akari, Yokoyama, Yuta, Ikawa, Kazuro, Morikawa, Norifumi, Takeda, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822798/
https://www.ncbi.nlm.nih.gov/pubmed/27099534
http://dx.doi.org/10.2147/CPAA.S96143
_version_ 1782425809828446208
author Matsumoto, Kazuaki
Watanabe, Erika
Kanazawa, Naoko
Fukamizu, Tomohide
Shigemi, Akari
Yokoyama, Yuta
Ikawa, Kazuro
Morikawa, Norifumi
Takeda, Yasuo
author_facet Matsumoto, Kazuaki
Watanabe, Erika
Kanazawa, Naoko
Fukamizu, Tomohide
Shigemi, Akari
Yokoyama, Yuta
Ikawa, Kazuro
Morikawa, Norifumi
Takeda, Yasuo
author_sort Matsumoto, Kazuaki
collection PubMed
description BACKGROUND: Teicoplanin is a glycopeptide antibiotic that has been used to treat serious, invasive infections caused by Gram-positive bacteria. The area under the drug concentration–time curve (AUC)/minimum inhibitory concentration (MIC) was identified as a pharmacokinetic–pharmacodynamic (PK–PD) parameter of glycopeptide antibiotics that correlated with bacteriological responses and clinical outcomes. Although optimized dosing regimens based on PK–PD are needed, a PK–PD analysis of teicoplanin against methicillin-resistant Staphylococcus aureus (MRSA) infections has not yet been performed. Thus, this study examined patients with MRSA infections, who were administered with teicoplanin in order to determine the target AUC/MIC ratio. METHODS: This study retrospectively assessed data obtained as part of our routine therapeutic drug monitoring (TDM) of teicoplanin therapy in 46 patients with MRSA infections at Kagoshima University Hospital. Serum concentrations of teicoplanin were determined using a fluorescence polarization immunoassay system and used for a Bayesian PK estimation to estimate AUC for 24 hours (AUC(24)). The MIC value for teicoplanin was determined using a standardized agar dilution method. The effects of teicoplanin were evaluated in terms of bacteriological responses by a quantitative assessment. RESULTS: The estimated AUC(24)/MIC ratios with and without bacteriological responses were 926.6±425.2 µg·h/mL (n=34) and 642.2±193.9 µg·h/mL, respectively (n=12; P<0.05). On the basis of a logistic regression analysis, AUC(24)/MIC ratios of 500 µg·h/mL, 700 µg·h/mL, and 900 µg·h/mL gave probabilities of treatment success of 0.50, 0.72, and 0.87, respectively. Furthermore, using the Kaplan–Meier curve analysis, an AUC(24)/MIC ratio of ≥900 led to a significantly stronger bacteriological response than an AUC(24)/MIC ratio of <900. CONCLUSION: These results suggest that an AUC(24)/MIC ratio of ≥900 µg·h/mL is required to ensure a sufficient bacteriological response.
format Online
Article
Text
id pubmed-4822798
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48227982016-04-20 Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections Matsumoto, Kazuaki Watanabe, Erika Kanazawa, Naoko Fukamizu, Tomohide Shigemi, Akari Yokoyama, Yuta Ikawa, Kazuro Morikawa, Norifumi Takeda, Yasuo Clin Pharmacol Original Research BACKGROUND: Teicoplanin is a glycopeptide antibiotic that has been used to treat serious, invasive infections caused by Gram-positive bacteria. The area under the drug concentration–time curve (AUC)/minimum inhibitory concentration (MIC) was identified as a pharmacokinetic–pharmacodynamic (PK–PD) parameter of glycopeptide antibiotics that correlated with bacteriological responses and clinical outcomes. Although optimized dosing regimens based on PK–PD are needed, a PK–PD analysis of teicoplanin against methicillin-resistant Staphylococcus aureus (MRSA) infections has not yet been performed. Thus, this study examined patients with MRSA infections, who were administered with teicoplanin in order to determine the target AUC/MIC ratio. METHODS: This study retrospectively assessed data obtained as part of our routine therapeutic drug monitoring (TDM) of teicoplanin therapy in 46 patients with MRSA infections at Kagoshima University Hospital. Serum concentrations of teicoplanin were determined using a fluorescence polarization immunoassay system and used for a Bayesian PK estimation to estimate AUC for 24 hours (AUC(24)). The MIC value for teicoplanin was determined using a standardized agar dilution method. The effects of teicoplanin were evaluated in terms of bacteriological responses by a quantitative assessment. RESULTS: The estimated AUC(24)/MIC ratios with and without bacteriological responses were 926.6±425.2 µg·h/mL (n=34) and 642.2±193.9 µg·h/mL, respectively (n=12; P<0.05). On the basis of a logistic regression analysis, AUC(24)/MIC ratios of 500 µg·h/mL, 700 µg·h/mL, and 900 µg·h/mL gave probabilities of treatment success of 0.50, 0.72, and 0.87, respectively. Furthermore, using the Kaplan–Meier curve analysis, an AUC(24)/MIC ratio of ≥900 led to a significantly stronger bacteriological response than an AUC(24)/MIC ratio of <900. CONCLUSION: These results suggest that an AUC(24)/MIC ratio of ≥900 µg·h/mL is required to ensure a sufficient bacteriological response. Dove Medical Press 2016-03-30 /pmc/articles/PMC4822798/ /pubmed/27099534 http://dx.doi.org/10.2147/CPAA.S96143 Text en © 2016 Matsumoto et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Matsumoto, Kazuaki
Watanabe, Erika
Kanazawa, Naoko
Fukamizu, Tomohide
Shigemi, Akari
Yokoyama, Yuta
Ikawa, Kazuro
Morikawa, Norifumi
Takeda, Yasuo
Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
title Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
title_full Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
title_fullStr Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
title_full_unstemmed Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
title_short Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
title_sort pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with mrsa infections
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822798/
https://www.ncbi.nlm.nih.gov/pubmed/27099534
http://dx.doi.org/10.2147/CPAA.S96143
work_keys_str_mv AT matsumotokazuaki pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections
AT watanabeerika pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections
AT kanazawanaoko pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections
AT fukamizutomohide pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections
AT shigemiakari pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections
AT yokoyamayuta pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections
AT ikawakazuro pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections
AT morikawanorifumi pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections
AT takedayasuo pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections